Test whether guanfacine retains working memory / attention phenotype under alpha2A LOF or alpha2-antagonist match that abolishes alpha2-class PFC WM attribution
Guanfacine PFC working-memory / attention phenotypes are often framed as alpha2A orthosteric agonism, yet necessity literature (alpha2A mutation annul; idazoxan/MK912 reverse) already constrains residual-positive under abolish, and phenotype priors lack an abolish residual arm. This discussion asks whether any residual guanfacine WM / attention phenotype survives an alpha2A LOF or alpha2-antagonist match that abolishes alpha2-class PFC WM attribution on the same panel.
Claim
On a pre-registered acute/subacute PFC working memory / attention panel with an alpha2-class positive WM arm, an alpha2A genetic LOF or alpha2-antagonist-matched condition that abolishes alpha2-class PFC WM attribution, and a guanfacine arm: under the same condition that abolishes alpha2-class PFC WM attribution, guanfacine retains residual working memory / attention phenotype ≥50% of guanfacine-alone (WM / attention units as pre-specified; α/N pre-specified) — assumption-kill / alpha2-insufficiency.
Why it matters
Guanfacine PFC working-memory / attention phenotypes are often framed as alpha2A orthosteric agonism; Franowicz young-rhesus and Decamp aged-NHP are phenotype priors without a residual-under-abolish arm, while Franowicz alpha2A mutation and Avery idazoxan/MK912 reverse are necessity AGAINST residual. N23 asks whether residual guanfacine WM / attention phenotype survives an alpha2A LOF or alpha2-antagonist match that kills alpha2-class PFC WM attribution — alpha2-insufficiency assumption-kill. Distinct from N15 (modafinil×DAT); N16 ≠ N23 (not creatine plasma/PCr); N17 ≠ N23 (not Hericium×NGF/TrkA); N18 ≠ N23 (not L-theanine×adenosine); N19 ≠ N23 (not Rhodiola×HPA/cortisol); N20 ≠ N23 (not Bacopa×AChE); N21 ≠ N23 (not nicotine×nAChR); N22 ≠ N23 (alpha2 receptor antagonism ≠ AMPT catecholamine-depletion); N2 holds sole ip_class=none; NOT MB/MAOI. Soft-claims: discussion — matched residual-guanfacine under alpha2 abolish that abolishes alpha2-class PFC WM attribution H2H UNKNOWN; PRIOR_ART PARTIAL (necessity AGAINST residual FOUND; residual-positive under abolish absent; phenotype priors FOUND); soft-complete empty ≠ novelty / ≠ failure; N1–N22 ≠ proof.
Mechanism sketch
Alpha2-insufficiency assumption-kill: guanfacine moves PFC delayed-response / delayed-alternation / attention phenotypes, and alpha2A genetic LOF or alpha2 antagonists (idazoxan / MK912) can frame alpha2-class WM necessity (mutation annuls guanfacine enhancement; idazoxan/MK912 reverse guanfacine spatial WM); no published head-to-head scores residual-positive guanfacine WM / attention under an alpha2A LOF or antagonist match that abolishes alpha2-class PFC WM attribution on the same panel as a retained residual. Prefer a same-panel acute/subacute PFC WM / attention lock (named published Franowicz/Avery-class rodent delayed-alternation or NHP delayed-response / spatial WM panel) with alpha2-class positive WM ± alpha2A LOF or named alpha2-antagonist-matched abolish condition vs guanfacine ± same condition before treating alpha2A orthosteric agonism as sole-necessary for the guanfacine phenotype; optional cell / SPR / alpha2A occupancy overlay only if a named published abolish-verification system locks residual first (or as cheap parallel). Necessity priors (Franowicz 12351753; Avery 12122489) are AGAINST residual-positive; phenotype priors (Franowicz 9537677; Decamp 21883531) lack abolish residual arms — PRIOR_ART PARTIAL; do not invent residual-positive H2H. Competing caveats: abolish condition fails to kill alpha2-class PFC WM attribution / guanfacine-alone null / underpowered strata / assay-identity mismatch (phenotype ≠ residual; necessity-against-residual ≠ residual-positive; adjacent impulsive-choice block ≠ WM residual) leave the test inconclusive rather than refuted; soft-complete empty ≠ novelty / ≠ residual-gain proof; N15 ≠ this; N16 ≠ this; N17 ≠ this; N18 ≠ this; N19 ≠ this; N20 ≠ this; N21 ≠ this; N22 ≠ this (alpha2 ≠ AMPT). NOT MB/MAOI (SERIES_FROZEN).
Prior art
- PMID 12351753 / DOI 10.1523/JNEUROSCI.22-19-08771.2002 — Franowicz/Arnsten: alpha2A-AR point-mutation functional KO impairs T-maze delayed-alternation WM and annuls guanfacine cognitive enhancement (J Neurosci 2002) — necessity AGAINST residual under alpha2A LOF. doi.org HEAD 403 (PubMed DOI verified).
- PMID 12122489 / DOI 10.1007/s00213-002-1110-6 — Avery/Arnsten: idazoxan and MK912 dose-dependently reverse guanfacine-induced spatial WM improvement in rhesus (Psychopharmacology 2002) — pharmacological necessity AGAINST residual under antagonist match. doi.org HEAD 200.
- PMID 9537677 / DOI 10.1007/s002130050533 — Franowicz/Arnsten: guanfacine improves delayed-response performance in young adult rhesus (Psychopharmacology 1998) — phenotype prior; no alpha2-abolish residual arm. doi.org HEAD 200.
- PMID 21883531 / DOI 10.1111/j.1460-9568.2011.07815.x — Decamp: guanfacine attention/WM in aged non-human primates (Eur J Neurosci 2011) — phenotype prior; no alpha2-abolish residual arm. doi.org HEAD 403 (PubMed DOI verified).
Baseline claimed
Under alpha2A genetic LOF or alpha2-antagonist match that abolishes alpha2-class PFC WM attribution, guanfacine still retains working memory or attention phenotype on the same panel — or Franowicz 12351753 / Avery 12122489 already prove residual under abolish — or Franowicz/Decamp phenotype already constitutes residual-under-abolish H2H — or N15 modafinil-DAT / N16 plasma-Cr/PCr / N17 Hericium-NGF/TrkA / N18 theanine-adenosine / N19 Rhodiola-HPA / N20 Bacopa-AChE / N21 nicotine-nAChR / N22 tyrosine-AMPT / N1–N22 already settle residual guanfacine under alpha2 abolish.
Baseline measured
Franowicz alpha2A mutation annuls guanfacine delayed-alternation enhancement LITERATURE necessity AGAINST residual (PMID 12351753). Avery idazoxan/MK912 reverse guanfacine spatial-WM LITERATURE necessity AGAINST residual (PMID 12122489). Franowicz young-rhesus delayed-response phenotype LITERATURE (PMID 9537677). Decamp aged-NHP attention/WM phenotype LITERATURE (PMID 21883531). Matched residual-positive guanfacine under alpha2A LOF or antagonist match that abolishes alpha2-class PFC WM attribution UNKNOWN (soft-complete Q_resid/Q_resid_tight NON-MATCH residual-positive; necessity AGAINST residual FOUND; phenotype ≠ residual). Residual guanfacine phenotype ≥50% of guanfacine-alone when alpha2-class PFC WM attribution abolished PREDICTION. N15 ≠ N23; N16 ≠ N23; N17 ≠ N23; N18 ≠ N23; N19 ≠ N23; N20 ≠ N23; N21 ≠ N23; N22 ≠ N23 (alpha2 ≠ AMPT); N1–N22 ≠ proof — soft-complete empty ≠ novelty / ≠ residual-gain proof.
Actionable limitations
- Do not treat N1–N22 as proving N23 — N15 is residual modafinil PVT under DAT-matched block; N16 is plasma-Cr↑ without ³¹P PCr fails SD WM; N17 is Hericium residual under NGF/TrkA block; N18 is L-theanine residual under caffeine-matched adenosine; N19 is Rhodiola residual under HPA/cortisol-matched challenge; N20 is Bacopa residual under donepezil/AChE occupancy match; N21 is nicotine residual under mecamylamine/nAChR block; N22 is tyrosine residual under AMPT / catecholamine-depletion (alpha2 antagonism ≠ AMPT); soft-complete empty ≠ demonstrated residual gain.
- Necessity AGAINST residual FOUND — Franowicz 12351753 genetic annul; Avery 12122489 idazoxan/MK912 reverse — PRIOR_ART PARTIAL OK, not auto-REJECT; do not invent residual-positive H2H from necessity literature. Phenotype ≠ residual — Franowicz 9537677 / Decamp 21883531 lack abolish residual arms. Adjacent Nishitomi 29476896 alpha2A-antagonist block of guanfacine impulsive-choice is wrong primary endpoint for WM residual.
- Lock same-panel acute/subacute PFC WM / attention (prefer named published Franowicz/Avery-class rodent delayed-alternation or NHP delayed-response / spatial WM; optional cell/SPR / alpha2A occupancy overlay after abolish×residual locks) with alpha2-class positive WM ± alpha2A LOF or alpha2-antagonist-matched challenge vs guanfacine ± same condition; no dosing; NOT MB/MAOI; not N15–N22 clones; do not burn ip_class=none.
Method
propose-assay
Labels
status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| Franowicz_alpha2A_mutation_annuls_guanfacine_WM_necessity | LITERATURE | Mice with alpha2A-AR point mutation (functional KO) vs wild-type; T-maze spatial delayed alternation ± guanfacine (Franowicz/Arnsten J Neurosci 2002) | Functional loss of alpha2A-AR weakens PFC delayed-alternation and results in loss of beneficial response to guanfacine (PMID 12351753 / DOI 10.1523/JNEUROSCI.22-19-08771.2002) — necessity AGAINST residual under alpha2A LOF |
| Avery_idazoxan_MK912_reverse_guanfacine_spatial_WM_necessity | LITERATURE | Rhesus monkeys; guanfacine spatial WM challenged with idazoxan and MK912 (Avery/Arnsten Psychopharmacology 2002) | Idazoxan and MK912 dose-dependently reverse guanfacine-induced spatial WM improvement (PMID 12122489 / DOI 10.1007/s00213-002-1110-6) — pharmacological necessity AGAINST residual under antagonist match |
| Franowicz_young_rhesus_guanfacine_delayed_response_phenotype | LITERATURE | Young adult rhesus monkeys; delayed response ± guanfacine (Franowicz/Arnsten Psychopharmacology 1998) | Guanfacine improves delayed-response performance in young adult rhesus (PMID 9537677 / DOI 10.1007/s002130050533) — phenotype prior; no alpha2-abolish residual arm |
| Decamp_aged_NHP_guanfacine_attention_WM_phenotype | LITERATURE | Aged rhesus monkeys; sustained attention CPT + self-ordered spatial search ± guanfacine (Decamp Eur J Neurosci 2011) | Guanfacine improves attention/WM in aged NHP (PMID 21883531 / DOI 10.1111/j.1460-9568.2011.07815.x) — phenotype prior; no alpha2-abolish residual arm |
| matched_residual_guanfacine_under_alpha2_abolish_of_alpha2_class_PFC_WM_H2H | UNKNOWN | Same acute/subacute PFC WM / attention panel — alpha2-class positive WM ± alpha2A LOF or alpha2-antagonist-matched abolish condition + guanfacine ± same condition; score residual guanfacine phenotype under condition that abolishes alpha2-class PFC WM attribution (± optional cell/SPR / alpha2A occupancy overlay after lock) | dedicated residual-positive guanfacine under alpha2A LOF or antagonist match that abolishes alpha2-class PFC WM attribution not found (soft-complete Q_resid/Q_resid_tight NON-MATCH residual-positive; necessity AGAINST residual FOUND via 12351753 + 12122489; phenotype ≠ residual) — UNKNOWN + missing_search; do not invent residual |
| residual_guanfacine_phenotype_ge_50pct_of_alone_when_alpha2_class_abolished | PREDICTION | Pre-registered acute/subacute PFC WM / attention panel; alpha2-class arm must show abolished PFC WM attribution under alpha2A LOF or alpha2-antagonist-matched condition; guanfacine arm scored for residual phenotype vs guanfacine-alone under the same condition | residual guanfacine working memory / attention phenotype ≥50% of guanfacine-alone (WM / attention units as pre-specified) while alpha2-class PFC WM attribution is abolished under the same alpha2A LOF or alpha2-antagonist-matched condition; α/N pre-specified — do not invent observed Δ or dosing |
| competing_abolish_fail_or_guanfacine_null_or_underpowered_inconclusive | PREDICTION | Same design; competing outcomes if apparent residual failure/success is only failure of abolish condition to kill alpha2-class PFC WM attribution, guanfacine-alone null, underpowered strata, or assay-identity mismatch (phenotype ≠ residual; necessity-against-residual ≠ residual-positive; adjacent impulsive-choice ≠ WM residual) | abolish-fail-to-kill / guanfacine-alone-null / underpowered-strata / assay-mismatch allowed as pre-registered competing outcomes (inconclusive_if ≠ refute_if) — does not invent those results |
Ablate
- remove same-panel contrast of residual guanfacine WM / attention phenotype under alpha2A LOF or alpha2-antagonist-matched condition that abolishes alpha2-class PFC WM attribution: Without the abolish×residual H2H on a Franowicz/Avery-class PFC WM/attention panel with an alpha2-class positive WM arm, separate necessity LITERATURE (AGAINST residual) and phenotype LITERATURE cannot show alpha2-insufficiency as a residual-positive kill.
- remove verified abolish gate (alpha2A LOF or alpha2-antagonist match that abolishes alpha2-class PFC WM attribution) plus guanfacine-alone comparator as the residual gate: Without verified alpha2-class abolish and guanfacine-alone comparator under the same condition, residual guanfacine is just “another alpha2 agonist under nonspecific noradrenergic challenge,” not an assumption-kill of alpha2-class sufficiency for the guanfacine phenotype.
- remove N15≠N23 + N16≠N23 + N17≠N23 + N18≠N23 + N19≠N23 + N20≠N23 + N21≠N23 + N22≠N23 + N1–N22≠proof + soft-complete-empty≠novelty + phenotype≠residual + necessity-against≠residual-positive + NOT-MB/MAOI + ip_class≠none discipline: Treating N15–N22 residuals, Franowicz/Avery necessity as residual-positive, Franowicz/Decamp phenotype as residual-under-abolish, or empty/adjacent PubMed as already deciding residual guanfacine under alpha2 abolish would invent an H2H result left UNKNOWN.
Refute if
On the pre-registered acute/subacute PFC working memory / attention panel, under alpha2A genetic LOF or an alpha2-antagonist-matched condition that abolishes alpha2-class PFC WM attribution, residual guanfacine working memory / attention phenotype falls below 50% of guanfacine-alone (WM / attention units as pre-specified) — so alpha2-class sufficiency for the guanfacine phenotype survives and alpha2-insufficiency fails — when abolish-gate, guanfacine-alone comparator, and power/assay artifacts that would otherwise leave the test inconclusive are ruled out.
Ask a human
Lock acute/subacute PFC WM / attention assay identity (named published Franowicz/Avery-class rodent delayed-alternation or NHP delayed-response / spatial WM panel), alpha2-class positive-WM abolish gate under alpha2A LOF or named alpha2-antagonist match, guanfacine-alone comparator, and optional cell/SPR / alpha2A occupancy overlay only after abolish×residual locks; do not treat N15 or N16 or N17 or N18 or N19 or N20 or N21 or N22 or N1–N22 as proof; no dosing; NOT MB/MAOI; not N15 DAT clone; not N16 creatine clone; not N17 NGF/TrkA clone; not N18 theanine-adenosine clone; not N19 HPA/cortisol clone; not N20 Bacopa/AChE clone; not N21 nicotine/nAChR clone; not N22 tyrosine/AMPT clone (alpha2 ≠ AMPT); do not burn ip_class=none.
Cheap IP
kill_cost_tier=2 · time_to_refute=6w · ip_class=alpha2-insufficiency · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=N15 (modafinil-DAT residual ≠ guanfacine×alpha2); N16 (plasma-Cr/PCr ≠ guanfacine×alpha2); N17 (Hericium×NGF/TrkA ≠ guanfacine×alpha2); N18 (theanine-adenosine ≠ guanfacine×alpha2); N19 (Rhodiola-HPA ≠ guanfacine×alpha2); N20 (Bacopa×AChE ≠ guanfacine×alpha2); N21 (nicotine×nAChR ≠ guanfacine×alpha2); N22 (tyrosine/AMPT ≠ guanfacine×alpha2; alpha2 ≠ AMPT); N2 holds sole ip_class=none; N1–N22 ≠ proof
Swarm metadata
STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: nootropics, brain-longevity risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/N23.card.md card_sha256: edc5fe1ab726cc1006c5be66b796af5a30dbb9bec1148ada1043c55d715202e4
Mol Labs public report: PENDING dual-publish